A new scientific statement from the Endocrine Society emphasizes health outcomes such as sleep apnea and heart disease over weight loss alone.
RT’s Three Key Takeaways:
- Holistic Health Focus: An Endocrine Society scientific statement recommends that obesity care prioritize treating related complications, including sleep apnea and cardiovascular disease, rather than focusing solely on weight loss.
- Therapeutic Comorbidity Benefits: Glucagon-like peptide-1 (GLP-1) based therapies show benefits for treating chronic comorbidities like respiratory and metabolic disorders, though questions remain regarding long-term outcomes and safety.
- Need for Long-Term Management: Because obesity is a complex, chronic condition, patients frequently regain weight and experience worsening blood pressure, cholesterol, and blood sugar levels when stopping treatment.
Obesity treatment strategies should be guided by improvements in overall patient health and comorbidity risk reduction rather than weight loss alone, according to a scientific statement released by the Endocrine Society published in Endocrine Reviews.
The authors emphasized that obesity is a complex, chronic disease driven by biological, genetic, metabolic, neurological, and environmental factors rather than personal willpower. According to the Endocrine Society, the disease affects more than 40% of American adults and accounts for more than $173 billion annually in US obesity-related healthcare and medical costs.
“This Statement highlights major advances in obesity science and outlines areas of research needed to improve our understanding of the disease, optimize treatment, personalize care and improve long-term health outcomes for people living with obesity,” said Daniel J Drucker, MD, lead author of the scientific statement writing group, in a news release. “The rapid adoption of highly effective obesity medications has changed the treatment landscape, but important questions remain about their long-term use, individualized treatment strategies, side effects and the best ways to measure treatment outcomes.”
Focus on Respiratory and Systemic Comorbidities
According to the statement, untreated obesity can lead to poor metabolic health, diminished mental health, and an impaired ability to perform basic physical tasks and movements required for everyday living.
The society highlighted that therapies such as semaglutide, tirzepatide, and other glucagon-like peptide-1 (GLP-1) receptor agonists have altered the management of obesity. Beyond reducing weight, these medications are being used to improve related conditions such as sleep apnea, heart disease, kidney disease, and liver disease. Researchers are also investigating their potential applications in arthritis, substance use disorders, infertility, and cancer.
However, the authors noted that safety considerations must be evaluated, including direct pharmaceutical effects, the physiological consequences of rapid weight loss, and unresolved uncertainties surrounding long-term patient outcomes.
Need for Continuous Care and Research Priorities
The scientific statement stressed that obesity requires ongoing, long-term therapeutic strategies. Evidence cited by the authors shows that individuals who discontinue treatment after reaching weight targets often regain weight and experience a recurrence or worsening of related health markers, including blood pressure, cholesterol levels, and blood glucose. Transitioning patients to lower-dose regimens or alternative medications, however, has been shown to assist in maintaining earlier weight loss gains.
To address current clinical gaps, the expert panel identified key research priorities to guide future investigations, including deeper evaluations of disease biology and personalized intervention protocols.
“Advancing research across these six priority areas will help transform obesity care by deepening our understanding of disease biology, improving treatment precision, defining meaningful clinical outcomes and optimizing the safe and effective use of emerging therapies,” said Drucker, of Mount Sinai Hospital in Toronto. “We need larger, longer and more diverse studies, as well as greater use of real-world data to understand treatment outcomes.”
